PMI Launches IQOS ILUMA in Macedonia

BusinessPMI by 2FIRSTS.ai
Nov.21.2023
PMI Launches IQOS ILUMA in Macedonia
Philip Morris International (PMI) has launched its new smoke-free device IQOS ILUMA in the Macedonia market.

According to a report by crnobelo on November 20, Philip Morris International (PMI) has launched its new smoke-free device, IQOS ILUMA, in the Macedonian market.

 

IQOS ILUMA will be introducing three different models in Macedonia: IQOS ILUMA PRIME, IQOS ILUMA, and IQOS ILUMA ONE. This series of products falls under the category of Heat-Not-Burn (HNB) devices, designed to cater to the diverse needs of adult users.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Study: Links between internalizing mental health symptoms and nicotine/tobacco use vary by gender identity among U.S. adolescents
Study: Links between internalizing mental health symptoms and nicotine/tobacco use vary by gender identity among U.S. adolescents
A study using 2020–2023 U.S. data from the ITC Youth Tobacco and Vaping Survey (ages 16–19) reports that both nicotine/tobacco use and internalizing mental health (IMH) symptoms vary across disaggregated gender identities, and that gender identity moderates the relationship between IMH symptoms and product use.
Feb.27 by 2FIRSTS.ai
Surrey councillor calls for tougher vape sales controls, seeking the “most restrictive legally supportable” package
Surrey councillor calls for tougher vape sales controls, seeking the “most restrictive legally supportable” package
Surrey Councillor Gordon Hepner presented a notice of motion calling on council to “wage war on vaping” by strengthening controls on the sale of vaping products in the city, citing vaping as a “serious health concern,” especially among youth. Hepner said the motion directs staff to bring back the “most restrictive legally supportable” package from the City’s 2019 bylaw work to materially reduce where and how vape products can be sold, including licensing controls and enforcement.
Feb.10 by 2FIRSTS.ai
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24
Elfbar warns flavour bans could push over 50,000 Scottish vapers back to smoking
Elfbar warns flavour bans could push over 50,000 Scottish vapers back to smoking
Elfbar said restricting vape flavour choices—potentially under the Tobacco and Vapes Bill—could disrupt established quitting behaviours and increase relapse risk among former smokers. An Opinium survey commissioned by the company reported fruit and sweet flavours have risen in popularity among adult vapers quitting smoking in Scotland, with 62% now using them most often to quit, up from 34% in December 2024.
Feb.28 by 2FIRSTS.ai
FRE Nicotine Pouches Partners with Taylor Reimer Racing, Covering Four 2026 ARCA Events
FRE Nicotine Pouches Partners with Taylor Reimer Racing, Covering Four 2026 ARCA Events
FRE® Nicotine Pouches announced a partnership with Taylor Reimer Racing, becoming the Official Nicotine Sponsor for four races in the 2026 ARCA Menards Series and serving as the primary sponsor at events in Alabama, Michigan, Minnesota, and Arizona. FRE branding will appear on the race car, driver suit, and helmet, and the collaboration will also extend to off-track content and activations.
Feb.27
Fontem Drops Texas Lawsuit and Plans to Refile in D.C. Over FDA Handling of Zone Application
Fontem Drops Texas Lawsuit and Plans to Refile in D.C. Over FDA Handling of Zone Application
Fontem US, the maker and seller of Zone nicotine pouches, has voluntarily dismissed its lawsuit against the U.S. Food and Drug Administration, which it had accused of unfairly delaying its market application.
Mar.25 by 2FIRSTS.ai